A clinician's view of voxelotor
Br J Haematol
.
2022 Nov;199(4):616-618.
doi: 10.1111/bjh.18455.
Epub 2022 Sep 16.
Authors
Ifeyinwa Osunkwo
1
,
Alan Anderson
2
,
R Clark Brown
3
,
Nirmish Shah
4
,
Jeremie H Estepp
5
Affiliations
1
Non-Malignant Hematology Section, The Levine Cancer Institute and Atrium Health, Charlotte, North Carolina, USA.
2
Prisma Health Comprehensive SCD Program, University of South Carolina School of Medicine, Greenville, South Carolina, USA.
3
Aflac Cancer and Blood Disorders Center, Children's Healthcare of Atlanta, Emory University School of Medicine, Atlanta, Georgia, USA.
4
Department of Medicine, Duke University, Durham, North Carolina, USA.
5
Departments of Global Pediatric Medicine and Hematology, St. Jude Children's Research Hospital, Memphis, Tennessee, USA.
PMID:
36113859
DOI:
10.1111/bjh.18455
No abstract available
Publication types
Letter
Research Support, Non-U.S. Gov't
MeSH terms
Benzaldehydes*
Humans
Pyrazines*
Pyrazoles
Substances
voxelotor
Benzaldehydes
Pyrazines
Pyrazoles